Compare UIS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UIS | AKBA |
|---|---|---|
| Founded | 1942 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.5M | 248.3M |
| IPO Year | 1994 | 2014 |
| Metric | UIS | AKBA |
|---|---|---|
| Price | $2.21 | $0.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $4.81 | $3.92 |
| AVG Volume (30 Days) | 587.8K | ★ 6.0M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,950,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.84 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $0.81 |
| 52 Week High | $4.98 | $3.19 |
| Indicator | UIS | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 35.17 |
| Support Level | $2.14 | N/A |
| Resistance Level | $2.61 | $0.98 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 13.55 | 11.57 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.